Human Immunodeficiency Virus (HIV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Human Immunodeficiency Virus (HIV) Market Outlook

Thelansis’s “Human Immunodeficiency Virus (HIV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Human Immunodeficiency Virus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Human Immunodeficiency Virus (HIV) Overview

Human immunodeficiency virus (HIV), a lentivirus in the retrovirus family, exhibits remarkable heterogeneity due to high viral load, rapid turnover rates, an error-prone reverse transcriptase enzyme, and viral genome recombination within infected individuals. Retroviruses, characterized by extended incubation periods, like HIV, gradually lead to clinical latency and eventual onset of AIDS symptoms, inflicting severe damage on the immune system by exploiting CD4+ cells for replication, ultimately destroying these cells. Zoonotic transmissions from nonhuman primates to humans have spawned diverse HIV lineages: HIV-1 groups M, N, O, and P and HIV-2 groups A-H. HIV-1 group M, responsible for the global pandemic, shares a direct but independent origin from SIVcpz in chimpanzees. For treating HIV infection, the FDA has approved over two dozen antiretroviral drugs, which can be categorized into six groups: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Fusion Inhibitors, Capsid Inhibitor, gp120 Attachment Inhibitor, and CCR5 Antagonist.

• In 2022, an estimated 1.3 million individuals worldwide acquired HIV, with women and girls accounting for 46% of new infections.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: